Annuaire scientifique

Thèmes de recherche développés

Publications CSM

2023

• A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
  Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X, Ambrosetti D, Kamenskaya A, Négrier S, Bernhard J-C, Borchiellini D, Cao Y, Pagès G
  mol 21 Feb 2023, 45

2022

• Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
  Pagnuzzi M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe M-A, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G
  Cancers 14(1) : 70
• Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti- angiogenic therapy
  Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
  BJU Int 2022 Jan;129(1):80-92
• Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
  Filipponi, D, Pagnuzzi M, Pagès G
  Cancers 14(9): 2095
• Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies
  Montemagno C, Luciano F, Pagès G
  Methods Mol Biol 2475:1-23
• Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
  Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M
  Cell Reports Medicine 3(9): 100659
• Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas
  Penco-Campillo M, Molina C, Piris P, Soufi N, Carré M, Pagnuzzi M, Picco V, , Dufies M, Ronco C, Benhida R, Martial S, Pagès G
  Cells 11(23), 3933

2021

• Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
  Dumond A, Montemagno C, Vial V, Grépin R, Pagès G
  Cells 10(5): 1222
• Cancer associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to antiangiogenic therapy
  Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
  BJU Int doi: 10.1111/bju.15506.
• Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
  Cooley L S, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K, Falciani F, Dufies M, Lambrechts D, Modave E, Chalopin-Fillot D, Pineau R, Ambrosetti D, Bernhard J-C, Ravaud A, Négrier S, Ferrero J-M, Pagès G, Benzekry S, Nikolsky M, Bikfalvi A
  Mol. Cancer 20:136
• Hypoxia and hypoxia-inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula
  Sadaghianloo N, Contenti J, Declemy S, Ambrosetti D, Zdralevic M, Tannour-Louet M, Fabbri L, Pagès G, Bost F, Hassen-Khodja R, Pouyssegur J, Jean-Baptise E, Dardik A, Mazure N M
  J Physiol 599: 2299-2321
• In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
  Montemagno C, Serrano B, Durivault J, Nataf V, Mocquot F, Amblard R, Vial V, Ronco C, Benhida R, Dufies M, Faraggi M, Pagès G
  Biochem Biophys Rep 27: 101098
• Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
  Dumond A, Brachet E, Durivault J, Vial V, Puszko A K, Lepelletier Y, Montemagno C, Pagnuzzi M, Hermine O, Garbay C, Lagarde N, Montes M, Demange L, Grépin R, Pagès G
  J Exp Clinical Cancer Research 40: 33
• Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
  Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G
  Int J Mol Sci 22, 6413
• Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
  Dufies M, Verbiest A, Cooley L S, Ndiaye P D, He W, Nottet N, Souleyreau W, Hagege A, Torrino S, Parola J, Giuliano S, Borchiellini D, Schiappa R, Mograbi B, Zucman-Rossi J, Bensalah K, Ravaud A, Auberger P, Bikfalvi A, Chamorey E, Rioux-Leclercq N, Mazure N M, Beuselinck B, Cao Y, Bernhard J C, Ambrosetti D, Pagès G
  Comm Biol 4: 166
• Relevance of Neuropilin 1 and Neuropilin 2 targeting for cancer treatment
  Dumond A, Pagès G
  J Cancer Immunol 3(2): 111-114
• The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
  Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y, Pagès G, Dufies M
  Theranostics 11(19): 9571-9586

2020

• Depicting the genetic architecture of pediatric cancers through an integrative gene network approach
  Savary C, Kim A, Lespagnol A, Gandemer V, Pellier I, Andrieu C, Pagès G, Galibert M-D, Blum Y, de Tayrac M
  Sci Rep 10: 1224
• Experimental models in neovascular age related macular degeneration
  Rastoin O, Pagès G, Dufies M
  Int J Mol Sci 21: 4627
• From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
  Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pagès G
  Int J Mol Sci 21(11): 4067
• Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients
  Dufies M, Fabbri L, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, Nottet N, Meyenberg Cunha de Padua M, Contenti J, Borchiellini D, Ferrero J-M, Rioux Leclercq N, Ambrosetti D, Mograbi B, Richard S, Viotti J, Chamorey E, Sadaghianloo N, Rouleau M, Craigen W J, Mari B, Clavel S, Pagès G, Pouyssegur J, Bost F, Mazure N M
  Theranostics 10(6): 2696-2713
• Les neuropilines : Des cibles pertinentes pour améliorer le traitement des cancers
  Dumond A, Demange L, Pagès G
  Med Sci (Paris) 36(5): 487-496
• Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
  Montemagno C, Pagès G
  Cancers 12(4): 821
• Neuropilins, as Relevant Oncology Target: Their Role in the Tumoral Microenvironment
  Dumond A, Pagès G
  Front Cell Dev Biol 8: 662
• Resistance to anti-angiogenic therapies: A mechanism depending on the time of exposure to the drugs
  Montemagno C, Pagès G
  Front Cell Dev Biol 8: 584
• Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
  Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J, Rioux-Leclercq N, Porta C, Négrier S, Ferrero J-M, Chamorey E, Pagès G, Dufies M
  Oncoimmunology 9:1, 1846901
• Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds
  Grytsai O, Valiashko O, Penco-Campillo M, Dufies M, Hagege A, Demange L, Martial S, Pagès G, Ronco C, Benhida R
  Bioorg Chem 104: 104271
• Targeting mesothelin in pancreatic ductal adeno-carcinoma (PDAC)
  Montemagno C, Pagès G
  J Cell Immunol 2(2): 65-67
• The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
  Grépin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel J F, Dupré F, Quintens H, Pagès G
  Theranostics 10(3): 1107-1121
• VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
  Penco-Campillo M, Comoglio Y, Feliz Morel A J, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi M, Morot A, Burel-Vandenbos F, Selby M, Williamson D, Clifford S C, Claren A, Doyen J, Picco V, Martial S, Pagès G
  Comm Biol 3(758): 579

2019

• 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
  Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pagès G, Fagret D, Broisat A, Ghezzi C
  Cancers 11(10): 1531
• In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer.
  Montemagno C , Dumas L, Cavaillès P, Ahmadi M, Bacot S, Debiossat M, Soubies A, Djaïleb L, Leenhardt J, De Leiris N, Dufies M, Pagès G, Hernot S, Devoogdt N, Perret P, Riou L, Fagret D, Ghezzi C, Broisat A
  Cancers 11(7). pii: E1039
• Inhibition of the amino‐acid transporter LAT1 demonstrates anti‐neoplastic activity in medulloblastoma
  Cormerais Y, Pagnuzzi M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe M F, Pagès G, Pouyssegur J, Picco V
  J Cell Mol Med 1-8
• New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
  Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G
  Theranostics 9(18): 5332–5346
• Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
  Giuliano S, Dufies M, Ndiaye P D, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero J-M, Mograbi B, Pagès G
  Theranostics 9(4): 1181-1199
• Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agent
  Brachet E, Dumond A, Liu W-Q, Fabre M, Selkti M, Raynaud F, Hermine O, Benhida R, Belmont P, Garbay C, Lepelletier Y, Ronco C, Pagès G, Demange L
  Bioorg Med Chem Lett 29:126710
• VEGF-C et vaisseaux lymphatiques. Une épée à double tranchant dans le développement tumoral et la dissémination métastatique
  Ndiaye P D, Pagès G
  Med Sci (Paris) 2(35): 132-137
• VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
  Ndiaye P D, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G
  Theranostics 9(3): 661-675

2018

• AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
  Brolih S, Parks S, Vial V, Durivault J, Mostosi L, Pouyssegur J, Pagès G, Picco V
  BMC Cancer 18(1): 249
• Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
  Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard J C, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero J M, Chamorey E, Blot-Chabaud M, Pagès G
  Theranostics 8(9): 2447-2458
• The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma
  Pagès G
  Oncotarget 9(60): 31564-31565
• The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma
  Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pagès G, Burel-Vandenbos F, Mazure N
  PLoS ONE 13(2): e0193477
• The tyrosine kinase inhibitor Sunitinib targets Vascular Endothelial (VE)-cadherin: a marker of response to antitumoral treatment in metastatic renal cell carcinoma
  Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada J-L, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero J-M, Escudier B, Négrier S, Pagès G, Vilgrain I
  Br J Cancer 118(9): 1179-1188

2017

• CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
  Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley L S, Ambrosetti D, Guyot M, Ndiaye P D, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacques A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero J M, Pagès G
  Br J Cancer 117(7): 947-953
• ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB
  Leduc M, Richard J, Costes S, Muller D, Varrault A, Compan V, Mathieu J, Tanti J F, Pagès G, Pouyssegur J, Bertrand G, Dalle S, Ravier M A
  Diabetologia 60(10): 1999-2010
• Extracellular Signal-Regulated Kinase Signaling in CD4-Expressing Cells Inhibits Osteochondromas
  Wehenkel M, Corr M, Guy C, Edwards B A, Castellaw A H, Calabrese C, Pagès G, Pouyssegur J, Vogel P, McGargill M A
  Front Immunol 8: 482
• NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model
  Liu W-Q, Lepelletier Y, Montes M, Borriello L, Jarray R, Grépin R, Leforban B, Loukaci A, Benhida R, Hermine O, Dufour S, Pagès G, Garbay C, Raynaud F, Hadj-Slimane R, Demange L
  Can Let 414: 88-98
• Spontaneous chondroma formation in CD2-Cre-driven Erk-deficient Mice
  Shiokawa M, Lu X, Miyake Y, Ishikawa E, Pagès G, Pouyssegur J, Ogata M, Yamasaki S
  Int Immunol 29(10): 479-485
• Structural and functional analysis of coral Hypoxia Inducible Factor
  Zoccola D, Morain J, Pagès G, Caminiti Segonds N, Giuliano S, Tambutté S, Allemand D
  PLoS ONE 12(11): e0186262
• Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
  Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye P D, Mastri M, Moghrabi W, Cooley L S, Ettaiche M, Chamorey E, Parola J, Vial V, Lupus-Plesu M, Bernhard J C, Ravaud A, Borchiellini D, Ferrero J M, Bikfalvi A, Ebos J M, Khabar K S, Grépin R, Pagès G
  Cancer Res 77(5): 1-15
• Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
  Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G
  Oncotarget 8(6): 9174-9188
• The c-Jun N-terminal kinase prevents oxidative stress induced by UV and thermal stresses in corals and human cells
  Picco V, Courtial L, Grover R, Cormerais Y, Rottier C, Labbe A, Pagès G, Ferrier-Pagès C
  Sci Rep 7: 45713
• Validation of commercial ERK antibodies against the ERK orthologue of the scleractinian coral Stylophora pistillata
  Picco V, Courtial L, Pagès G, Ferrier-Pagès C
  F1000Res 6(577)

2016

• ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2
  Picco V, Coste I, Giraud-Panis M-J, Renno T, Gilson E, Pagès G
  Oncotarget 7(29): 46615-46627
• Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
  Zakraoui O, Marcinkiewicz C, Aloui Z, Othman H, Grépin R, Haoues M, Essafi M, Srairi-Abid N, Gasmi A, Karoui H, Pagès G, Essafi-Benkhadir K
  Mol Carcinog 56(1): 18-35
• Molecular assessment of the effect of light and heterotrophy in the scleractinian coral Stylophora pistillata
  Levy O, Karako-Lampert S, Waldman Ben-Asher H, Zoccola D, Pagès G, Ferrier-Pagès C
  Proc Biol Sci 283(1829)
• Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins.
  Hitti E, Bakheet T, Al-Souhibani N, Moghrabi W, Al-Yahya S, Al-Ghamdi M, Al-Saif M, Shoukri M M, Lanczk A, Grépin R, Gyorffy B, Pagès G, Khabar K S
  Cancer Res 76(14): 4068-4080
• Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma
  Picco V, Benhamou Y, Raybaud H, Sudaka A, Chamorey E, Brolih S, Monteverde M, Merlano M, Nigro C L, Ambrosetti D, Pagès G
  Oncotarget 7(28): 44236-44251
• The telomere proteins in tumorigenesis and clinical outcomes of oral squamous cell carcinoma
  Benhamou Y, Picco V, Pagès G
  Adaptation and Evolution in Marine Environments 57: 46-53

2015

• Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
  Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure N M, Benhida R, Auberger P, Mograbi B, Pagès G
  Autophagy 11(10): 1891-1904
• Transient Blockade of ERK Phosphorylation in the Critical Period Causes Autistic Phenotypes as an Adult in Mice
  Yufune S, Satoh Y, Takamatsu I, Ohta H, Kobayashi Y, Takaenoki Y, Pagès G, Pouyssegur J, Endo S, Kazama T
  Sci Rep 20(5): 10252

2014

• Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways
  Grépin R, Guyot M, Pagès G
  Molecular Mechanisms of Angiogenesis Springer Paris, Chap. 20: 397-419
• The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma
  Grépin R, Guyot M, Giuliano S, Pagnuzzi M, Ambrosetti D, Chamorey E, Scoazec J Y, Negrier S, Simonnet H, Pagès G
  Cancer Res 74(3): 873-883
• The ELRCXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
  Giuliano S, Guyot M, Grépin R, Pagès G
  Oncoimmunology 3: e28399
• The Relevance of Testing the Efficacy of Anti-Angiogenesis Treatments on Cells Derived from Primary Tumors: A New Method for the Personalized Treatment of Renal Cell Carcinoma
  Grépin R, Ambrosetti D, Marsaud A, Gastaud L, Amiel J, Pedeutour F, Pagès G
  PLoS ONE 9(3): e89449

2013

• Linking JNK Activity to the DNA Damage Response
  Picco V, Pagès G
  Genes Cancer 4(9-10): 360-368